| Contributors: |
Ostrowska, A; Wojciechowska, W; Rajzer, M; Weber, T; Bursztyn, M; Persu, A; Stergiou, G; Kiełbasa, G; Chrostowska, M; Doumas, M; Parati, G; Bilo, G; Grassi, G; Mancia, G; Januszewicz, A; Kreutz, R; Narkiewicz, K; Dubiela, A; Imprialos, K; Stavropoulos, K; de Freminville, J; Azizi, M; Cunha, P; Lewandowski, J; Strzelczyk, J; Wuerzner, G; Gosk-Przybyłek, M; Szwęch, E; Prejbisz, A; Van der Niepen, P; Kahan, T; Jekell, A; Spaak, J; Tsioufis, K; Ehret, G; Doroszko, A; Kubalski, P; Polonia, J; Styczkiewicz, K; Styczkiewicz, M; Mazur, S; Veglio, F; Rabbia, F; Eula, E; Águila, F; Sarzani, R; Spannella, F; Jarai, Z; Papadopoulos, D; Sublet, M; Grassos, C; Kahrimanidis, I; Gkaliagkousi, E; Triantafyllou, A; Grodzicki, T; Wizner, B; Seweryn, A; Moczulska, B; Ntineri, A; Robles, N; Widmiski, J; Zbroch, E |
| Description: |
Objective: The COVID-19 pandemic had a major impact on medical care. This study evaluated the influence of the pandemic on blood pressure (BP) control and hypertension phenotypes as assessed by office and 24-hour ambulatory BP monitoring (ABPM). Design and Methods: Data were collected from 33 centers including Excellence Centers of the European Society of Hypertension. Two groups of patients with treated hypertension were compared. Pandemic group: including participants who had ABPM twice - at visit 2 during the COVID-19 pandemic and visit 1 performed 9–15 months prior to visit 2. Pre-pandemic group: had ABPM at two visits, performed before the pandemic within 9–15 months interval. We determined the following hypertension phenotypes: masked hypertension, white coat hypertension, sustained controlled hypertension (SCH) and sustained uncontrolled hypertension (SUCH). We analyzed the prevalence of phenotypes and their changes between visits. Results: Data of 1419 patients, 616 (43 %) in the pandemic group and 803 (57 %) in the pre-pandemic group, were analyzed. At baseline (visit 1), the prevalence of hypertension phenotypes did not differ between groups. In the pandemic group, the change in hypertension phenotypes between two visits was not significant (p = 0.08). In contrast, in the pre-pandemic group, the prevalence of SCH increased during follow-up (28.8 % vs 38.4 %, p < 0.01) while the prevalence of SUCH decreased (34.2 % vs 27.8 %, p < 0.01). In multivariable adjusted analysis, the only factor influencing negative changes of hypertension phenotypes was the COVID-19 pandemic period. Conclusion: These results indicate a negative impact of the COVID-19 pandemic on BP control assessed by hypertension phenotypes. |